AAM Women in Health Policy Happy Hour

Wednesday April 4, 2018

Thursday, April 19, 2018 – 5-7pm – 601 New Jersey Ave. NW

Join The Biosimilars Council and the Association for Accessible Medicines for cocktails and networking with other women in health policy. This nonpartisan event will be an opportunity to reconnect with old colleagues and meet new ones. All are welcome!

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:


GRx+Biosims 2020

Planning + Ready: Join us November 9-11, 2020 for the premier scientific and regulatory event for the U.S. generics and biosimilars industries.


Recent Tweets

If the entire Affordable Care Act (#ACA) is overturned as unconstitutional, it could eliminate the Biologics Price Competition and Innovation Act (#BPCIA) and threaten the accessibility of life-saving treatments in the U.S.

Read more: https://www.washingtonpost.com/opinions/letters-to-the-editor/striking-down-obamacare-would-also-nix-generic-biologic-drugs/2020/06/28/44a4a630-b7c4-11ea-9a1d-d3db1cbe07ce_story.html

Load More...

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.